K2VC — 2026 Investments

1 investments dated 2026 · listed companies and verified rows first · show all

Apollomicsapollomicsinc.com in 𝕏Aug 2026

Apollomics is a biotechnology company focused on discovering and developing oncology therapies designed to combine with other treatments, using approaches that engage the immune system and target specific molecular pathways to inhibit cancer.

BiotechHealthtechFoster City, US

Peter Lin(Executive Officer)Guo-Liang Yu(Founder)Sanjeev Redkar(Founder)

BoardHung-Wen (Howard) Chen(Executive Officer, Director)Hung-Hsien Yen(Director)Yi-Kuei (Alex) Chen(Executive Officer, Director)

Co-investorsMaxpro Ventures Pan-Lin Capital Qiming Venture Partners SVE Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.